Drug news
Ameluz has CHMP recommendation for Actinic Keratosis
The Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Ameluz (5-aminolevulinic acid) from Biofrontera AG for the treatment of actinic keratosis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.